![81Eaiw6YAiL._CLa|2841,2339|91Kx8JcipqL.jpg,81ywsNORC0L.jpg|0,0,1291,2339+1550,0,1291,2339+645,0,1550,2339_._SY200_.jpg 81Eaiw6YAiL._CLa|2841,2339|91Kx8JcipqL.jpg,81ywsNORC0L.jpg|0,0,1291,2339+1550,0,1291,2339+645,0,1550,2339_._SY200_.jpg](https://m.media-amazon.com/images/W/IMAGERENDERING_521856-T1/images/I/81Eaiw6YAiL._CLa%7C2841,2339%7C91Kx8JcipqL.jpg,81ywsNORC0L.jpg%7C0,0,1291,2339+1550,0,1291,2339+645,0,1550,2339_._SY200_.jpg)
81Eaiw6YAiL._CLa|2841,2339|91Kx8JcipqL.jpg,81ywsNORC0L.jpg|0,0,1291,2339+1550,0,1291,2339+645,0,1550,2339_._SY200_.jpg
![Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/jm2007613/asset/images/large/jm-2011-007613_0019.jpeg)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry
![Suspiria : Dakota Johnson, Tilda Swinton, Mia Goth, David Kajganich, Luca Guadagnino, Bradley J. Fischer: Amazon.de: Prime Video Suspiria : Dakota Johnson, Tilda Swinton, Mia Goth, David Kajganich, Luca Guadagnino, Bradley J. Fischer: Amazon.de: Prime Video](https://images-na.ssl-images-amazon.com/images/W/IMAGERENDERING_521856-T1/images/S/pv-target-images/0abd7b70c62f1177f82d240cb7835a583425333b88e67679b09d41c817a2f3af._RI_.jpg)